CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

gaboxadol

Small moleculeexperimental

Gaboxadol, also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP), as well as by its former developmental code names LU-2-030 and OV101, is a conformationally constrained derivative of the alkaloid and Amanita muscaria constituent muscimol. It acts as a direct GABAA receptor agonist. At lower doses, the drug has sedative and hypnotic effects, and at higher doses, it has hallucinogenic effects. Gaboxadol was studied for potential medical use as a pharmaceutical drug for a variety of indications, most notably treatment of insomnia, but was ultimately never marketed. — Wikipedia

Clinical trial activity

23 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
21
Phase 3
14
Phase 4
0

Earliest trial started Jan 1, 2003 (NCT00209937)

Timeline

2000s

  1. Jan 1, 2003

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2005

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Oc1noc2c1CCNC2
Mol. weight
140.14 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol
  • 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol
  • 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol
  • gaboxadol
  • gaboxadol
  • gaboxadol
  • gaboxadol
  • gaboxadol
  • lu-02030
  • lu-02030
  • lu 2030
  • lu-2-030
  • mk-0928
  • mk-0928
  • ov101
  • thip
  • thip
  • thip

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06334419Phase 2Jan 29, 2024Healx Limited, University of Cincinnati
NCT05901480N/AJun 26, 2023—
NCT04106557Phase 3Sep 9, 2019Ovid Therapeutics Inc.
NCT03882918Phase 2Feb 25, 2019Ovid Therapeutics Inc.
NCT03697161Phase 2Sep 17, 2018Ovid Therapeutics Inc.
NCT03109756Phase 1Apr 3, 2017Ovid Therapeutics Inc.
NCT02996305Phase 2Jan 1, 2016Ovid Therapeutics Inc.
NCT00807248Phase 2Nov 1, 2008Lundbeck
NCT00420810Phase 3Sep 1, 2006Lundbeck, Merck
NCT00266344Phase 2Nov 1, 2005Lundbeck, Merck
NCT00266357Phase 2Nov 1, 2005Lundbeck, Merck
NCT00103818Phase 3Feb 1, 2005Lundbeck, Merck
NCT00102167Phase 3Feb 1, 2005Lundbeck, Merck
NCT00102154Phase 3Jan 1, 2005Lundbeck, Merck
NCT00094627Phase 3Nov 1, 2004Lundbeck, Merck
NCT00094666Phase 3Nov 1, 2004Lundbeck, Merck
NCT00095043Phase 3Oct 1, 2004Lundbeck, Merck
NCT00095069Phase 3Oct 1, 2004Lundbeck, Merck
NCT00209950Phase 3Jul 1, 2004Lundbeck
NCT00209846Phase 3Jun 1, 2004Lundbeck
Showing 20 of 23 trials
Page 1 / 2

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
LundbeckFor profit161622003
MerckFor profit10022004
Ovid Therapeutics Inc.For profit5532016
Healx LimitedFor profit1012024
University of CincinnatiAcademic/Hospital1112024
5 organizations
Page 1 / 1